[breadcrumb_custom]

Does Astria Therapeutics Inc (NASDAQ:ATXS) Look Expensive At $15.00? Here’s How To Know.

In last trading session, Astria Therapeutics Inc (NASDAQ:ATXS) saw 0.48 million shares changing hands with its beta currently measuring 0.73. Company’s recent per share price level of $15.00 trading at -$0.26 or -1.70% at ring of the bell on the day assigns it a market valuation of $820.05M. That closing price of ATXS’s stock is at a discount of -4.33% from its 52-week high price of $15.65 and is indicating a premium of 71.6% from its 52-week low price of $4.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.16 million shares which gives us an average trading volume of 665.53K if we extend that period to 3-months.

Astria Therapeutics Inc (NASDAQ:ATXS) trade information

Upright in the red during last session for losing -1.70%, in the last five days ATXS remained trading in the green while hitting it’s week-highest on Thursday, 02/08/24 when the stock touched $15.00 price level, adding 4.15% to its value on the day. Astria Therapeutics Inc’s shares saw a change of 95.31% in year-to-date performance and have moved 14.50% in past 5-day. Astria Therapeutics Inc (NASDAQ:ATXS) showed a performance of 101.07% in past 30-days. Number of shares sold short was 1.44 million shares which calculate 1.65 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Astria Therapeutics Inc (ATXS) estimates and forecasts

Statistics highlight that Astria Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 77.30% of value to its shares in past 6 months, showing an annual growth rate of 35.77% while that of industry is 15.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -8.30% in the current quarter and calculating -37.50% decrease in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 45.77% during past 5 years.

ATXS Dividends

Astria Therapeutics Inc is more likely to be releasing its next quarterly report between March 20 and March 25 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Astria Therapeutics Inc (NASDAQ:ATXS)’s Major holders

Insiders are in possession of 0.49% of company’s total shares while institution are holding 65.51 percent of that, with stock having share float percentage of 65.83%. Investors also watch the number of corporate investors in a company very closely, which is 65.51% institutions for Astria Therapeutics Inc that are currently holding shares of the company. FMR, LLC is the top institutional holder at ATXS for having 2.96 million shares of worth $24.68 million. And as of Jun 29, 2023, it was holding 10.56% of the company’s outstanding shares.

The second largest institutional holder is Perceptive Advisors Llc, which was holding about 2.19 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 7.81% of outstanding shares, having a total worth of $18.24 million.

On the other hand, Fidelity Advisor Biotechnology Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2023, the former fund manager was holding 1.29 million shares of worth $11.55 million or 4.60% of the total outstanding shares. The later fund manager was in possession of 0.92 million shares on Jun 29, 2023, making its stake of worth around $7.62 million in the company or a holder of 3.26% of company’s stock.

On Key

Related Posts